NCT05961956View on ClinicalTrials.gov

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 15, 2025

Conditions
Degenerative Lumbar Spondylolisthesis
Interventions
DRUG

NVDX3

NVDX3 is implanted during a single surgical intervention.

Trial Locations (1)

1210

Centre Hospitalier de Luxembourg, Luxembourg

Sponsors

Collaborators (1)

PrimeVigilance
All Listed Sponsors
collaborator

PrimeVigilance

INDUSTRY

collaborator

Data Investigation Company Europe (DICE)

UNKNOWN

lead

Novadip Biosciences

INDUSTRY